ReviewMicroorganisms2020
Review in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 90 citations in OpenAlex.
- Kombucha-Mediated Silver Nanoparticles with Fungicidal Activity Against WHO-PriorityCurrent issues in molecular biology · 2026Article
- The chromatin remodeling factor Arp9 modulates drug-resistance and plays a key role in aflatoxins biosynthesis under mammalian-physiological-temperature in Aspergillus flavus.PLoS pathogens · 2026Article
- Review
- Integrative computational-experimental discovery and translation of antifungal peptides for multidrug-resistant fungi.Frontiers in microbiology · 2026Review
- Salvianolic acid B synergizes with azoles againstFrontiers in cellular and infection microbiology · 2026Article
- In Vivo Evaluation of Efficacy and Toxicity of Bioinspired Peptides With Antimicrobial Properties Against Fungal Infection inInternational journal of microbiology · 2026Article
- Drug Discovery and Repurposing forJournal of fungi (Basel, Switzerland) · 2025Review
- Biological Activity of Silver(I)-1,10-Phenanthroline Complexes AgainstPharmaceuticals (Basel, Switzerland) · 2025Article
- Caspofungin binding to iron compromises its antifungal efficacy against Candida albicans.Communications biology · 2025Article
- The role of innate immunity, antibiotics, and bacteriophages in the course of bacterial infections and their treatment.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The role of innate immunity, antibiotics, and bacteriophages in the course of bacterial infections and their treatment.bioRxiv : the preprint server for biology · 2025Article
- Uncovering the antifungal potential of Cannabidiol and Cannabidivarin.PLoS neglected tropical diseases · 2025Article
- Humanized Candida and NanoBiT Assays Expedite Discovery of Bdf1 Bromodomain Inhibitors With Antifungal Potential.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Therapeutic alternatives for sporotrichosis induced by wild-type and non-wild-type Sporothrix schenckii through in vitro and in vivo assessment of enilconazole, isavuconazole, posaconazole, and terbinafine.Scientific reports · 2025Article
- Sensitive bioluminescence imaging of cryptococcosis inVirulence · 2024Article
- Toxicological Assessment of 2-Hydroxychalcone-Mediated Photodynamic Therapy: Comparative In Vitro and In Vivo Approaches.Pharmaceutics · 2024Article
- Article
- Sunflower Oil and Cholesterol Nanoemulsion: A Novel Carrier for Micafungin to Combat Multi-ResistantPathogens (Basel, Switzerland) · 2024Article
- Review
- Chitosan nanoparticles encapsulating farnesol evaluated in vivo against Candida albicans.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of invasive fungal infections remains challenging and the emergence of new fungal pathogens as well as the development of resistance to the main antifungal drugs highlight the need for novel therapeutic strategies. Although in vitro antifungal susceptibility testing has come of age, the proper evaluation of therapeutic efficacy of current or new antifungals is dependent on the use of animal models. Mammalian models, particularly using rodents, are the cornerstone for evaluation of antifungal efficacy, but are limited by increased costs and ethical considerations. To circumvent these limitations, alternative invertebrate models, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.